APTIVA
LIVE

Serial Number

88071814

Owner

Inova Diagnostics, Inc.

Attorney

Deborah J Peckham

First Use Date

Jan 18, 2021

Filing Date

Aug 9, 2018

Add to watchlist:

No watchlists yet
View on USPTO

APTIVA Trademark

Serial Number: 88071814 • Registration: 6316056

APTIVA is a trademark filed by Inova Diagnostics, Inc. on August 9, 2018. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 10 (Medical Apparatus). The application is currently registered and active.

Owner Contact Info

Inova Diagnostics, Inc.

9900 Old Grove Rd
San Diego, CA 92131

Entity Type: 03

Trademark Details

Filing Date

August 9, 2018

Registration Date

April 6, 2021

First Use Anywhere

January 18, 2021

First Use in Commerce

January 18, 2021

Published for Opposition

June 9, 2020

Goods & Services

Laboratory apparatus for testing of plasma, serum, sputum, fecal, and urine samples for research purposes; all of the foregoing for use in connection with a fluorescence multi-analyte immunoassay system for laboratory research use and not for use in connection with detecting nucleic acid

Apparatus and instruments for medical diagnosis, namely, medical apparatus for diagnosing, monitoring, and treating gastrointestinal, neurological, autoimmune, infectious, hepatological, rheumatologic, nephrological, dermatological, coagulation, endocrine, pulmonologic, immune system related, and respiratory diseases; all of the foregoing for use in connection with a fluorescence multi-analyte immunoassay system for medical diagnostic use and not for use in connection with detecting nucleic acid

Pharmaceutical and veterinary products, namely, fluorescence multi-analyte immunoassay system for medical diagnostic use, namely, gastrointestinal, neurological, autoimmune, infectious, hepatological, rheumatologic, nephrological, dermatological, coagulation, endocrine, pulmonologic, immune system related, and respiratory diseases; clinical diagnostic assays for medical purposes, namely, identifying and diagnosing of gastrointestinal, neurological, autoimmune, infectious, hepatological, rheumatologic, nephrological, dermatological, coagulation, endocrine, pulmonologic, immune system related, and respiratory diseases; all of the foregoing for use in connection with a fluorescence multi-analyte immunoassay system for medical diagnostic use and not for use in connection with detecting nucleic acid

Chemical products for scientific purposes, namely, biomarkers for scientific testing; reagents for scientific and research use; all of the foregoing for use in connection with a fluorescence multi-analyte immunoassay system for medical research use and not for use in connection with detecting nucleic acid

Filing History

COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Apr 6, 2026 REM1
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Mar 27, 2025 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Mar 27, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Mar 27, 2025 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Mar 27, 2025 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Mar 27, 2025 COAR
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jul 22, 2022 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jul 22, 2022 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jul 22, 2022 REAP
REGISTERED-PRINCIPAL REGISTER
Apr 6, 2021 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Feb 27, 2021 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Feb 26, 2021 CNPR
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 13, 2021 EXRA
STATEMENT OF USE PROCESSING COMPLETE
Feb 12, 2021 SUPC
SOU EXTENSION 1 GRANTED
Feb 12, 2021 EX1G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Feb 12, 2021 AITU
USE AMENDMENT FILED
Jan 29, 2021 IUAF
SOU EXTENSION 1 FILED
Jan 29, 2021 EXT1
SOU TEAS EXTENSION RECEIVED
Jan 29, 2021 EEXT
TEAS STATEMENT OF USE RECEIVED
Jan 29, 2021 EISU
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Aug 4, 2020 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 9, 2020 NPUB
PUBLISHED FOR OPPOSITION
Jun 9, 2020 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 20, 2020 NONP
ELECTRONIC RECORD REVIEW COMPLETE
May 4, 2020 FIXD
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
May 1, 2020 ERRR
EXPARTE APPEAL TERMINATED
Apr 29, 2020 EXPT
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 29, 2020 CNSA
ASSIGNED TO LIE
Apr 28, 2020 ALIE
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Apr 24, 2020 ERFR
EX PARTE APPEAL-INSTITUTED
Apr 24, 2020 EXPI
JURISDICTION RESTORED TO EXAMINING ATTORNEY
Apr 24, 2020 JURT
EXPARTE APPEAL RECEIVED AT TTAB
Apr 24, 2020 EXAF
NOTIFICATION OF FINAL REFUSAL EMAILED
Apr 14, 2020 GNFN
FINAL REFUSAL E-MAILED
Apr 14, 2020 GNFR
FINAL REFUSAL WRITTEN
Apr 14, 2020 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 11, 2020 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 11, 2020 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Mar 11, 2020 ERSI
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Jan 25, 2020 GNS2
INQUIRY TO SUSPENSION E-MAILED
Jan 25, 2020 GNSI
SUSPENSION INQUIRY WRITTEN
Jan 25, 2020 CNSI
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Jul 2, 2019 GNS3
LETTER OF SUSPENSION E-MAILED
Jul 2, 2019 GNSL
SUSPENSION LETTER WRITTEN
Jul 2, 2019 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 11, 2019 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 11, 2019 CRFA
ASSIGNED TO LIE
Jun 11, 2019 ALIE
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Jun 6, 2019 ERSI
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Jun 5, 2019 GNS3
LETTER OF SUSPENSION E-MAILED
Jun 5, 2019 GNSL
SUSPENSION LETTER WRITTEN
Jun 5, 2019 CNSL
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
May 16, 2019 AMPX
TEAS VOLUNTARY AMENDMENT RECEIVED
May 16, 2019 PARI
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Dec 6, 2018 GNRN
NON-FINAL ACTION E-MAILED
Dec 6, 2018 GNRT
NON-FINAL ACTION WRITTEN
Dec 6, 2018 CNRT
ASSIGNED TO EXAMINER
Nov 28, 2018 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 16, 2018 NWOS
NEW APPLICATION ENTERED
Aug 13, 2018 NWAP